66th ASH Annual Meeting: Advances in Paroxysmal Nocturnal Hemoglobinuria: Reshaping Management Decision-Making through Case Challenges Together with the International PNH Interest Group

Sponsor: This program is supported by the International PNH Interest Group and educational grants from Alexion, Apellis and Sobi

Friday Satellite Symposia

Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Diseases

Ballroom 20AB (San Diego Convention Center)

Chairs:

Petra Muus, MD, St James's University Hospital and Charles Parker, University of Utah School of Medicine

Disclosures:

Muus: Roche: Membership on an entity's Board of Directors or advisory committees; Sobi Middle East: Speakers Bureau; Novartis UK: Membership on an entity's Board of Directors or advisory committees; Novartis Global: Membership on an entity's Board of Directors or advisory committees; Alexion: Membership on an entity's Board of Directors or advisory committees.

Speakers:

Morag Griffin, MBChB, MRCP, Leeds Teaching Hospitals , Jeffrey Szer, MBBS, ARRAY(0xeed7ec4) , Phillip Scheinberg, MD, Hospital A Beneficência Portuguesa , Richard J. Kelly, MBChB, PhD, Leeds Teaching Hospitals NHS Trust , Alexander Röth, MD, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Jens Panse, MD, University Hospital RWTH Aachen , Bing Han, Peking Union Medical College Hospital , Carlos M de Castro, MD, Duke University , Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP, King's College Hospital NHS Foundation Trust , Rodrigo T. Calado, MD, PhD, University of Sao Paulo and Britta Hoechsmann, MD, Institute for Clinical Transfusion Medicine and Immunogenetics, University of Ulm

Disclosures:

Griffin: Sobi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Biocryst: Consultancy; Alexion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Omeros: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Regeneron Pharmaceuticals: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Szer: Sobi Pharmaceuticals: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADARx: Consultancy; Eli Lilly: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Samsung Bioepis: Consultancy; Alexion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Scheinberg: Pfizer: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy; Astellas: Consultancy; Janssen: Consultancy; Roche: Consultancy, Speakers Bureau; Alnylam: Research Funding; Novartis: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau.

In this symposium the International PNH Interest Group (IPIG) aims to provide an update on recent developments in PNH, including the status of IPIG’s guidelines and the status of IPIG’s newly developed international patient registry. Using case-based scenarios, experts in the field will describe their approach to the use of proximal complement inhibitors; treatment of patients with concurrent bone marrow failure and use of bone marrow transplant in PNH. A special panel session with 6 experts from different countries will focus on management of breakthrough hemolysis during treatment with terminal or early complement inhibitors.

See more of: Friday Satellite Symposia

<< Previous Application | Next Application >>